NO20054778L - Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer - Google Patents

Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Info

Publication number: NO20054778L
Authority: NO; Norway
Prior art keywords: rapamycin; inflammatory; treatment; combination; pharmaceutical compositions
Prior art date: 2003-03-17

Application number

NO20054778A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054778D0 (no

Inventor

Henrietta Moore

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-17

Filing date

2005-10-17

Publication date

2005-12-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054778(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-17 Priority claimed from GB0306070A external-priority patent/GB0306070D0/en

2003-03-25 Priority claimed from GB0306868A external-priority patent/GB0306868D0/en

2003-08-15 Priority claimed from GB0319226A external-priority patent/GB0319226D0/en

2005-10-17 Application filed by Novartis Ag filed Critical Novartis Ag

2005-10-17 Publication of NO20054778D0 publication Critical patent/NO20054778D0/no

2005-12-19 Publication of NO20054778L publication Critical patent/NO20054778L/no

Links

QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 3
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
230000002757 inflammatory effect Effects 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 title 1
229960005330 pimecrolimus Drugs 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
206010061598 Immunodeficiency Diseases 0.000 abstract 1
208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000007813 immunodeficiency Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Obesity (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

NO20054778A 2003-03-17 2005-10-17 Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer NO20054778L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0306070A GB0306070D0 (en)	2003-03-17	2003-03-17	Organic compounds
GB0306868A GB0306868D0 (en)	2003-03-25	2003-03-25	Organic compounds
GB0319226A GB0319226D0 (en)	2003-08-15	2003-08-15	Organic compounds
PCT/EP2004/002714 WO2004082681A1 (en)	2003-03-17	2004-03-16	Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases

Publications (2)

Publication Number	Publication Date
NO20054778D0 NO20054778D0 (no)	2005-10-17
NO20054778L true NO20054778L (no)	2005-12-19

Family

ID=33032928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054778A NO20054778L (no)	2003-03-17	2005-10-17	Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Country Status (25)

Country	Link
US (1)	US20060154952A1 (pl)
EP (1)	EP1608368B8 (pl)
JP (1)	JP2006515017A (pl)
KR (1)	KR100855140B1 (pl)
AR (1)	AR043504A1 (pl)
AT (1)	ATE409479T1 (pl)
AU (1)	AU2004222563B2 (pl)
BR (1)	BRPI0408423A (pl)
CA (2)	CA2517671A1 (pl)
CL (1)	CL2004000535A1 (pl)
DE (1)	DE602004016830D1 (pl)
EC (1)	ECSP056006A (pl)
ES (1)	ES2315648T3 (pl)
HR (1)	HRP20050800A2 (pl)
IS (1)	IS8028A (pl)
MA (1)	MA27671A1 (pl)
MX (1)	MXPA05009934A (pl)
MY (1)	MY137868A (pl)
NO (1)	NO20054778L (pl)
PE (1)	PE20050313A1 (pl)
PL (1)	PL1608368T3 (pl)
PT (1)	PT1608368E (pl)
TN (1)	TNSN05197A1 (pl)
TW (2)	TW200503703A (pl)
WO (1)	WO2004082681A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20070070184A (ko) *	2004-10-28	2007-07-03	와이어쓰	자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
CA2719134C (en) *	2008-03-21	2015-06-30	The University Of Chicago	Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
AU2010206840B2 (en)	2009-01-21	2015-02-05	Amgen Inc.	Compositions and methods of treating inflammatory and autoimmune diseases
RU2449806C1 (ru) *	2010-11-30	2012-05-10	Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию"	Способ лечения красного плоского лишая слизистой оболочки полости рта
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
JP6529012B2 (ja)	2013-10-08	2019-06-12	エイアイ・セラピューティクス・インコーポレーテッド	リンパ脈管筋腫症の処置のためのラパマイシン
NZ724756A (en)	2014-04-04	2023-07-28	Ai Therapeutics Inc	An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru)	2014-10-07	2020-09-24	ЭйАй ТЕРАПЬЮТИКС, ИНК.	Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
CR20170510A (es)	2015-04-10	2018-02-26	Amgen Inc	Muteínas de interuquina 2 para la expansión de células t regulatorias
EP3565520B1 (en)	2017-01-06	2026-02-25	Palvella Therapeutics, Inc.	Anhydrous compositions of mtor inhibitors and methods of use
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
PH12022550326A1 (en)	2019-08-13	2023-03-13	Amgen Inc	Interleukin-2 muteins for the expansion of t-regulatory cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0427680T3 (da) *	1989-11-09	1995-12-18	Sandoz Ltd	Heteroatom-holdige cykliske forbindelser
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
FR2736550B1 (fr) *	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT956034E (pt) *	1996-07-30	2002-12-31	Novartis Ag	Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
GB9723669D0 (en) *	1997-11-07	1998-01-07	Univ Aberdeen	Skin penetration enhancing components
BR0209474A (pt) *	2001-05-09	2006-02-07	Novartis Ag	Métodos para imunomodulação seletiva
BR0306858A (pt) *	2002-01-10	2004-11-03	Novartis Ag	Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
EP1501565B1 (de) *	2002-05-09	2006-11-02	Hemoteq GmbH	Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen

2004
- 2004-03-08 AR ARP040100730A patent/AR043504A1/es not_active Application Discontinuation
- 2004-03-15 PE PE2004000273A patent/PE20050313A1/es not_active Application Discontinuation
- 2004-03-15 TW TW093106848A patent/TW200503703A/zh unknown
- 2004-03-15 TW TW097116133A patent/TW200835484A/zh unknown
- 2004-03-16 KR KR1020057017469A patent/KR100855140B1/ko not_active Expired - Fee Related
- 2004-03-16 JP JP2005518678A patent/JP2006515017A/ja active Pending
- 2004-03-16 AU AU2004222563A patent/AU2004222563B2/en not_active Ceased
- 2004-03-16 PL PL04720871T patent/PL1608368T3/pl unknown
- 2004-03-16 MX MXPA05009934A patent/MXPA05009934A/es not_active Application Discontinuation
- 2004-03-16 DE DE602004016830T patent/DE602004016830D1/de not_active Expired - Fee Related
- 2004-03-16 CA CA002517671A patent/CA2517671A1/en not_active Abandoned
- 2004-03-16 WO PCT/EP2004/002714 patent/WO2004082681A1/en not_active Ceased
- 2004-03-16 US US10/547,185 patent/US20060154952A1/en not_active Abandoned
- 2004-03-16 HR HR20050800A patent/HRP20050800A2/xx not_active Application Discontinuation
- 2004-03-16 CA CA002633287A patent/CA2633287A1/en not_active Abandoned
- 2004-03-16 EP EP04720871A patent/EP1608368B8/en not_active Expired - Lifetime
- 2004-03-16 CL CL200400535A patent/CL2004000535A1/es unknown
- 2004-03-16 BR BRPI0408423-3A patent/BRPI0408423A/pt not_active IP Right Cessation
- 2004-03-16 ES ES04720871T patent/ES2315648T3/es not_active Expired - Lifetime
- 2004-03-16 PT PT04720871T patent/PT1608368E/pt unknown
- 2004-03-16 AT AT04720871T patent/ATE409479T1/de not_active IP Right Cessation
- 2004-03-16 MY MYPI20040914A patent/MY137868A/en unknown
2005
- 2005-08-17 TN TNP2005000197A patent/TNSN05197A1/en unknown
- 2005-09-08 EC EC2005006006A patent/ECSP056006A/es unknown
- 2005-09-15 IS IS8028A patent/IS8028A/is unknown
- 2005-09-30 MA MA28526A patent/MA27671A1/fr unknown
- 2005-10-17 NO NO20054778A patent/NO20054778L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2004222563A1 (en)	2004-09-30
PE20050313A1 (es)	2005-06-14
IS8028A (is)	2005-09-15
CA2633287A1 (en)	2004-09-30
EP1608368B1 (en)	2008-10-01
DE602004016830D1 (de)	2008-11-13
US20060154952A1 (en)	2006-07-13
KR100855140B1 (ko)	2008-08-28
ES2315648T3 (es)	2009-04-01
MXPA05009934A (es)	2006-03-21
JP2006515017A (ja)	2006-05-18
KR20050110023A (ko)	2005-11-22
BRPI0408423A (pt)	2006-03-21
NO20054778D0 (no)	2005-10-17
ATE409479T1 (de)	2008-10-15
HRP20050800A2 (en)	2006-11-30
ECSP056006A (es)	2006-01-27
MY137868A (en)	2009-03-31
HK1086743A1 (en)	2006-09-29
WO2004082681A1 (en)	2004-09-30
EP1608368A1 (en)	2005-12-28
EP1608368B8 (en)	2009-06-10
AR043504A1 (es)	2005-08-03
TNSN05197A1 (en)	2007-06-11
CL2004000535A1 (es)	2005-01-14
TW200835484A (en)	2008-09-01
TW200503703A (en)	2005-02-01
MA27671A1 (fr)	2005-12-01
PT1608368E (pt)	2009-01-27
WO2004082681B1 (en)	2004-11-25
PL1608368T3 (pl)	2009-03-31
AU2004222563B2 (en)	2006-11-02
CA2517671A1 (en)	2004-09-30

Legal Events

Date	Code	Title	Description
2009-10-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20076059L (no)	2008-01-30	2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
NO20054778L (no)	2005-12-19	Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
NO20051100L (no)	2005-05-02	Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
AP2008A (en)	2009-06-29	Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them
DE60224404D1 (de)	2008-02-14	Substiuierte piperidine als melanocortinrezeptor-modulatoren
NO20070489L (no)	2007-03-07	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20072371L (no)	2007-07-12	Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20062561L (no)	2006-09-08	Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
EA200802058A1 (ru)	2009-06-30	Производные циклоалкиламинокислот и их фармацевтические композиции
NO20084005L (no)	2008-09-19	Aminderivater
ATE361288T1 (de)	2007-05-15	N-(3,-dimethylindolin-6-yl)ä2-ä(4-
NO20063928L (no)	2006-10-31	Substituerte kinolinforbindelser
DE602004024900D1 (de)	2010-02-11	Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
NO20054905L (no)	2006-01-25	2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
CY1109055T1 (el)	2014-07-02	11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
NO20062983L (no)	2006-07-24	Sulfonamid-derivater for behandling av sykdommer
NO20061363L (no)	2006-04-24	Pyrazolo- og imidazo- pyrimidinderivater
NO20060278L (no)	2006-03-15	Piperazinderivater og fremgangsmater for anvendelse
NO20073170L (no)	2007-06-22	Kaspaseinhibitorer og anvendelse derav
ATE406353T1 (de)	2008-09-15	Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten
NO20062021L (no)	2006-07-07	Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20062256L (no)	2006-06-06	Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
BR0318521A (pt)	2006-09-12	arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados